A detailed history of Entry Point Capital, LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Entry Point Capital, LLC holds 47,520 shares of ADPT stock, worth $298,900. This represents 0.14% of its overall portfolio holdings.

Number of Shares
47,520
Holding current value
$298,900
% of portfolio
0.14%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.37 - $5.12 $160,142 - $243,302
47,520 New
47,520 $243,000
Q1 2024

May 14, 2024

SELL
$2.88 - $4.8 $24,174 - $40,291
-8,394 Reduced 25.15%
24,986 $80.2 Million
Q4 2023

Feb 14, 2024

BUY
$3.46 - $5.33 $115,494 - $177,915
33,380 New
33,380 $164 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $899M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.